Planned Daewoong-HanAll Merger Hit By Union Protests
This article was originally published in PharmAsia News
The planned acquisition of South Korea’s HanAll Biopharma by its bigger rival Daewoong Pharmaceutical has met a setback as unionized workers are HanAll protesting the plan, demanding compensation and job security amid concerns over the transaction.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.